article thumbnail

Nitrosamines analysis with LC/MS-MS

European Pharmaceutical Review

In recent years, nitrosamines have been detected in various medicines, leading to voluntary product recalls from the market. Nitrosamines analysis is, thus, key to ensuring safety and quality in the pharmaceutical industry.

article thumbnail

AstraZeneca partnership to pioneer UK’s first commercial biomethane supply

European Pharmaceutical Review

The pharma company’s sites in Macclesfield, Cambridge, Luton and Speke will be supplied by energy from the biomethane facility. A total of 100 gigawatt hours (GWh) per year, equivalent to the heat demands of over 8,000 homes will be supplied. This increases renewable energy capacity to the national gas grid.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Switzerland and US sign drug inspection agreement

European Pharmaceutical Review

Under the agreement with the Swiss Confederation (Switzerland), the Swiss Agency for Therapeutic Products (Swissmedic) and the US Food and Drug Administration (FDA) will be able to utilise each other’s GMP inspections of pharmaceutical manufacturing facilities, avoiding the need for duplicate inspections.

article thumbnail

Is the pharmaceutical sector realising its potential for sustainable manufacturing?

European Pharmaceutical Review

Globally, the pharmaceutical sector emitted around 52 megatonnes of CO 2 in 2015, the most recent period for which detailed numbers are available. megatonnes in the same year, and the increased demand and complexity of medicines since then will only have swollen this figure. 1 That’s more than the automotive sector, which released 46.4

article thumbnail

FDA completes inspection of Nexus’ manufacturing facility in US

Pharma Leaders

The Food and Drug Administration (FDA) has successfully inspected Nexus Pharmaceuticalspharmaceutical manufacturing facility located in Pleasant Prairie, Wisconsin, US. The inspection will allow the company to commence commercial operations at the three-storey, 84,000ft² manufacturing facility.

article thumbnail

Key developments in pharmaceutical manufacturing – September 2023

European Pharmaceutical Review

September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. Research by the Confederation of British Industry (CBI) , released in September this year, highlighted progress for UK manufacturing in its latest Industrial Trends Survey. Meath opened last month.

article thumbnail

Curbing AMR through sustainable antibiotic manufacturing

European Pharmaceutical Review

[pharmaceutical companies] must take measures to manage antibiotic waste across the manufacturing supply chain” 2023 has so far, delivered a spectrum of change for antibiotic manufacturers across the pharmaceutical industry, from supply chain issues through to regulatory opportunities.